August 16, 2023 Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
August 14, 2023 Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
July 31, 2023 Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
June 15, 2023 Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 12, 2023 Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
May 12, 2023 Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights